Clinical Trial Update: Darolutamide With Radium-223 or Placebo and the Effect on Radiological Progression-Free Survival for Patients With mCSPC [Phase 3]

View source ↗

Summary

Phase 3 trial investigating darolutamide with radium-223 or placebo in metastatic castration-resistant prostate cancer was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Darolutamide (darolutamide)
• Radium-223 (radium-223 dichloride)

Snippet

Sponsor: GenesisCare USA | Conditions: Metastatic Prostate Cancer | Phase 3 | Status: WITHDRAWN